Form 4: Trevi Therapeutics Director Colangelo Acquires 30,000 Stock Options

Dominick Colangelo, a director of Trevi Therapeutics, acquired 30,000 nonstatutory stock options on June 13, 2024.

Summary

• On June 13, 2024, Dominick Colangelo, a director of Trevi Therapeutics, Inc. (TRVI), acquired 30,000 nonstatutory stock options.
• The options have an exercise price of $2.77.
• The options vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders, contingent upon continued service.
• The options expire on June 12, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director suggests confidence in the company, but it's a routine transaction.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon continued service as a director, employee, or consultant, suggesting an expectation of ongoing involvement with the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates